CervoMed reports Q2 2026 results, seeks partner for neflamapimod Phase 3 in DLB
The company disclosed new AAIC data supporting a 50 mg dose, an ILAP designation in the UK, and cash runway into the third quarter of 2027.
CervoMed Inc. reported second quarter 2026 financial results on August 10, 2026, and said its primary strategic objective is securing a partner to support the advancement of neflamapimod into Phase 3 and realize its potential for patients living with DLB, according to CEO John Alam.1
In August 2026, neflamapimod was awarded an Innovation Passport designation to enter the United Kingdom's ILAP for development in dementia with Lewy bodies (DLB), a designation the company said recognizes the therapy as addressing a condition of high unmet need with potential for a major therapeutic advantage.1
At the Alzheimer's Association International Conference, the company presented exploratory analyses of its Phase 2b RewinD-LB trial. It said the study's primary endpoint result was affected by a higher-than-targeted proportion of patients with Alzheimer's disease co-pathology and by a drug product batch that underachieved target plasma concentrations, rather than a lack of treatment effect.1 A pharmacokinetic analysis identified a trough plasma drug concentration threshold of about 4 ng/mL associated with clinical and biomarker improvement, supporting the company's selection of 50 mg TID as the dose for its planned Phase 3 trial, expected to achieve this threshold in about 90% of patients.1
In the frontotemporal dementia program, CervoMed announced completion of enrollment in July 2026 in its Phase 2a trial evaluating neflamapimod for nonfluent variant primary progressive aphasia, with 25 participants enrolled.1 Biomarker data are planned for the ISFTD conference in October and the CTAD conference in November 2026, with topline clinical data and additional biomarker data expected in the first quarter of 2027.1
Separately, CervoMed ended enrollment in June 2026 in its Phase 2a RESTORE trial in patients recovering from acute ischemic stroke,1 with topline data expected in the second half of 2026, and it expects to dose the first ALS patient by the end of 2026.
On financing, CervoMed completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, before about $1.9 million in fees.1 As of June 30, 2026, the company held approximately $24.9 million in cash, cash equivalents and marketable securities, up from $20.9 million at year-end 2025, and said this is expected to fund operations through the third quarter of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.